



**Mansoura University**

**Faculty of medicine**

**Pathology Department**

***Role of minimal panel immuestaining  
in accurate diagnosis of lung cancer  
using small biopsies***

***By***

**Manar Ahmed Abdel Rahman El Sayed**

**Manar** Ahmed Abdel Rahman\*, **Nadia**  
Abdel Moneim Nada\*, **Khaled** Refaat  
Zalata\*, **Mohammad** Khairy El  
Badrawy \*\*, **Iman** Mohammed El  
Salkh\*, **Amr** Abdel Hamid \*\*

Department of Pathology\* & Thoracic  
Medicine \*\*

**Faculty of Medicine, Mansoura**  
**University, Egypt**

❑ **Lung cancer** is a leading cause of cancer deaths world wide.

❑ **In Egypt**, according to statistics released by **National Cancer Institute**, lung cancer cases represent 8.2% of total cancer cases in men and about 2.4% of total cancer among women .

❑ **Cancer lung** is related to cigarette smoking.

Siegel R, et al., 2012 - El-Bolkainy M et al., 2012

□ **Many methods** are available for pathologic diagnosis of lung cancer important among which are : Sputum cytology, bronchial brushing, invasive procedures such as **bronchoscopic biopsy** and bronchial lavage are widely used in diagnosis of lung cancers .

Travis et al., 2012

□ Because **70%** of lung cancers are **unresectable** as patients present in advanced stages, **small biopsy** and cytology specimens are the primary method of diagnosis for the majority of lung cancer patients. All received specimens in this work are small biopsy.

Travis et al., 2011

**Immunohistochemistry** is a valuable tool in diagnosis of lung cancer especially in small biopsy. The importance of the IASLC 2011 new classification of lung cancer in small biopsies has been simplified also. In this study we used minimal panel for diagnosis of lung cancer. This panel included **Napsin A, CK 5/6 & CD 56.**

## **Aim of work**

We aim in this study to apply recommendations of International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS) /European Respiratory Society (ERS) on diagnosis of lung cancer in small biopsies and to define role of immunohistochemical staining in definitive diagnosis and subcategorization of lung cancer .

## Patient and method

This is a prospective case series of **86 patients** with lung cancer either central or peripheral.

**All cases** admitted or referred to chest medicine department, Mansoura University from the period between April 2012 and April 2014.

**Fiberoptic bronchoscope** biopsy is used for central lung tumors in 70 cases and trans thoracic CT guided for peripheral lung tumor in 16 cases.

Patient consent was done for all cases.



<b>Antigen</b>	<b>Localization of expression</b>	<b>Scoring of tumor intensity</b>	<b>Scoring of % positive tumor cell</b>
<b>Napsin A</b>	<b>Granular cytoplasmic</b>	<b>0 negative 1 weak 2 intermediate 3 strong</b>	<b>Score 1: 1-9% Score 2: 10 – 49% Score 3: &gt; 50%</b>
<b>CK5/6</b>	<b>Cytoplasmic</b>	<b>The same</b>	<b>As napsin-A</b>
<b>CD56</b>	<b>Cytoplasmic or membranous</b>	<b>The same</b>	<b>&gt; 10% tumor cells</b>

**Data were analyzed with SPSS version 16.**

# Results

# Histologic subtypes of lung cancer among the studied cases according to WHO 2004 classification of lung cancer (morphological diagnosis by H&E) (n=84)

Types		n	(%)
ADC	Acinar pattern	9	<b><u>47.6</u></b>
	Solid pattern with mucin production	8	
	Papillary pattern	1	
	Non mucinous bronchioalveolar	2	
	Mucinous type bronchioalveolar	1	
	Mixed pattern	19	
	Total	40	
SCC		10	11.9
LCC		22	26.2
Neuroendocrine tumors	Small Cell Carcinoma	10	14.3
	Atypical carcinoid	2	

**histologic subtypes of tumors after immune staining with Napsin A , CK5/6 , CD56 (n=84)  
(According to IASLC 2011)**

<b>Tumor Cell Types</b>	<b>n</b>	<b>%</b>
<b>ADC</b>	<b>54</b>	<b>64.3</b>
<b>SCC</b>	<b>11</b>	<b>13.1</b>
<b>NSCL (NOS)</b>	<b>8</b>	<b>9.5</b>
<b>Neuroendocrine tumors</b>	<b>11</b>	<b>13.1</b>

**This table shows that adenocarcinoma is the most common histologic subtype of lung cancer representing 64.3% of the total cases .**

## ♠ What is NSCLC (NOS) ?

Term present only in IASLC 2011 classification & in 2015 WHO classification of lung cancer.

It's counterpart to large cell carcinoma in 2004 WHO classification of lung cancer.

**NSCLC (NOS)  
(28 Cases)**

**19 Cases**  
**Napsin A +ve**  
**CK 5/6 -ve**  
**CD 56 -ve**

**1 Case**  
**Napsin A -ve**  
**CK 5/6 -ve**

**8 Cases**  
**Napsin A -ve**  
**CK 5/6 -ve**  
**CD 56 -ve**

**Final  
Diagnosis**

**NSCLC favor of  
adenocarcinoma**

**NSCLC favor of  
SQCC**

**NSCLC (NOS)**

**So,**

**after use of immunostain  
number of NSCLC (NOS)  
decreased from 33.3% to  
9.5% .**

# Adenocarcinoma cases

19 cases  
(NSCLC favor  
of ADC)

Previously  
explained

13 cases  
solid predominant  
adenocarcinoma  
(morphological  
diagnosis)

12 Case  
Napsin A +ve  
CK 5/6 -ve

1 Case  
Napsin A -ve  
CK 5/6 -ve

1 case  
micropapillary  
predominant ADC  
(morphologic diagnosis)  
Napsin A +ve  
TTF 1 +ve

5 cases  
papillary predominant  
adenocarcinoma  
(morphologic diagnosis)  
Napsin A +ve  
TTF 1 +ve

16 cases  
( Well differentiated ADC )  
14 acinar , 2 lepidic  
(morphologic diagnosis)  
Napsin A +ve



**So,**


**cases of adenocarcinoma  
increased after use of  
immunestain from 47.6% to  
64.3% .**

**Why we added TTF-1 to Napsin A in diagnosis of paillary and the micropapillary variants of adenocarcinoma ?**

# Change in diagnosis of adenocarcinoma after immunohistochemistry

	All cases n = 54	Solid	Acinar	Papillary	Lepidic	Micro papillary
1 stain	Napsin A +ve		14		2	
	Napsin A -ve					
2 stains	Napsin A +ve – CK5/6 -ve	12				
	Napsin A -ve – CK5/6 -ve	1		5		
3 stains	Napsin A +ve – TTF1+ve					1
	Napsin A +ve – CK5/6 -ve – CD56 -ve	19				

# Squamous cell carcinoma (SQCC)



**Why we added Napsin A to  
CK 5/6 in SQC cases ?**

**To exclude squamoid  
variant of adenocarcinoma.**

**NET**  
**11 cases**

6 cases  
(Small cell carcinoma)  
CD 56 +ve

2 cases  
(Small cell carcinoma)  
CD 56 +ve  
CD 5/6 -ve


1 case  
Napsin A -ve  
CK 5/6 -ve  
CD 56 +ve

2 Cases  
NSCLC with  
NEM possible  
LCNEC


1 Case  
Napsin A -ve  
CD 56 +ve

1 Case  
Napsin A -ve  
CK 5/6 -ve  
CD 56 +ve

**Both have KI 67 > 80 %**




**H&E 200x**




**CK 5/6 400x**

**A case of NSCLC(NOS) proved to be squamous cell carcinoma. A) H&E shows malignant cells with abundant cytoplasm, vesicular nuclei and marked atypia x200. B) Positive cytoplasmic staining of tumor cells for ck5/6 ImmunoPeroxidase-DAB x400. C,D) Negative staining.**




**H&E 200x**




**Napsin A 400x**

**Acinar predominant adenocarcinoma : A) H&E shows tumor cells consists of round to oval-shaped malignant glands separated by desmoplastic reaction x200. B) Strong intensity staining of tumor cells for napsin A, ImmunoPeroxidase-DAB x400**






**H&E 400x**




**CD 56 400x**

A case of small cell carcinoma. A) H&E showing malignant round to fusiform cells growing in sheets and nests. The nuclei appears ovoid with moulding and hyperchromasia x400. B) Positive cytoplasmic staining of tumor cells for CD56 tumor cells (score 3) Immunoperoxidase-DAB x400.



**H&E 400x**



**CD 56 200x**

**A case Non small cell lung carcinoma with neuroendocrine morphology possible large cell neuroendocrine carcinoma (NSCLC with NEM possible NCLEC). A) H&E solid pattern of tumor growth morphologically similar to photo 1 x400. However by doing immunostains proved the following: B) Positive cytoplasmic staining of tumor cells for CD56Immunoperoxidase-DAB x\200**

## Conclusion & home message

**Immunohistochemistry** has valuable role in precise typing of different pulmonary tumors, a minimal panel of **Napsin A, CK 5/6 & CD 56** is helpful in accurate and final diagnosis of lung cancer in small biopsies .

## **Conclusion & home message**

**The use of the three antibodies is done in this work aiming to minimize the term NSCLC – NOS on small samples providing as specific a histologic classification as possible to facilitate treatment approach of medical oncologist.**

**(Mok et al., 2009 & Boyle and Levin, 2008)**

## **Conclusion & home message**

**In this study adenocarcinoma was the commonest subtype in young male .**

## **Conclusion & home message**

**The increasing number of adenocarcinoma cases may be due to the increase of the cases of (Non small cell lung carcinoma favour adenocarcinoma) after use of immunostain and this goes with other reports. This was in agreement with Righiet al., 2011 .**

## **Conclusion & home message**

**Although adenocarcinoma is still a morphological diagnosis but the variant (NSCLC favour ADC) need the panel done in this study**

## **Conclusion & home message**

**In the squamous cell carcinoma either well or moderate cases we are not in need to do immunohistochemistry.**



## **Conclusion & home message**

**The category Non Small Cell Lung carcinoma favour squamous cell carcinoma is diagnosed only by using immunohistochemistry.**

## **Conclusion & home message**

**Both Napsin A and CK 5/6 have pivotal role in diagnosis and differential diagnosis of adenocarcinoma and squamous cell carcinoma respectively .**

## **Conclusion & home message**

**As regard neuroendocrine tumors diagnosis of small cell carcinoma not needed immuno-histochemistry.**

**However we applied CD56 to confirm neuroendocrine features and to exclude small cell variant of squamous cell carcinoma, lymphoma and other blue round cell tumor.**

## **Conclusion & home message**

**The diagnosis of LCNEC is difficult to establish based on small biopsies or cytology. This is related to difficulty to do immunohistochemistry and to detect neuroendocrine pattern in such small biopsy.**

## **Conclusion & home message**

**As a whole, immunohistochemical stains should be interpreted with caution especially in the setting of markedly crushed biopsy with otherwise uninterpretable morphology .**

*Thank You*